The use of staging 18F-FDG PET in management and prognosis of patients with small cell lung carcinoma
- Dr Sze Ting Lee, Centre for PET; Ludwig Institute for Cancer Research; Department of Medicine, Austin Hospital, Victoria, Australia
|
Quantitative 201Tl SPECT in assessing malignant astrocytomas
- Dr Geoffrey P Schembri, Royal North Shore Hospital, Australia
|
Role of CT/PET in predicting nodal disease in head and neck cancers
- Dr Shahlini Singham, Australia
|
Phase I biodistribution and pharmacokinetic study of Lewis Y targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
- Andrew M Scott, Ludwig Institute for Cancer Research, Department of Nuclear Medicine & Centre for PET, Austin Hospital, Melbounre, Australia
|
Impact of FDG-PET on delineation for radiotherapy in lung cancer
- Dr Kavita Morarji, Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia
|
18F–Fluoromisonidazole (FMISO) and 18F–fluorodeoxyglucose (FDG) PET in patients undergoing radiotherapy or chemotherapy following surgery for high-grade glioma
- Dr Sze Ting Lee, Centre for PET; Department of Medicine; Ludwig Institute for Cancer Research, Austin Hospital, Victoria, Australia
|
Monitoring cellular proliferation during chemo-radiotherapy: A pilot study of serial 18F-FLT-PET/CT scanning for Non-Small Cell Lung Cancer
- Mrs Sarah J Everitt, Peter MacCallum Cancer Centre, Monash University, Australia
|
